CN108403932A - 一种治疗激素依赖性皮炎的中药复方外用制剂及其制备方法和应用 - Google Patents
一种治疗激素依赖性皮炎的中药复方外用制剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN108403932A CN108403932A CN201810511418.7A CN201810511418A CN108403932A CN 108403932 A CN108403932 A CN 108403932A CN 201810511418 A CN201810511418 A CN 201810511418A CN 108403932 A CN108403932 A CN 108403932A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine compound
- preparation
- steroid dependent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 137
- 150000001875 compounds Chemical class 0.000 title claims abstract description 75
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 62
- 230000001419 dependent effect Effects 0.000 title claims abstract description 52
- 150000003431 steroids Chemical class 0.000 title claims abstract description 48
- 230000000694 effects Effects 0.000 claims abstract description 46
- 229940079593 drug Drugs 0.000 claims abstract description 37
- 244000197580 Poria cocos Species 0.000 claims abstract description 26
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 26
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 21
- 239000000463 material Substances 0.000 claims abstract description 20
- 238000000605 extraction Methods 0.000 claims abstract description 19
- 241000411851 herbal medicine Species 0.000 claims abstract description 12
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract 8
- 241000723353 Chrysanthemum Species 0.000 claims abstract 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 66
- 235000019441 ethanol Nutrition 0.000 claims description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- 239000005556 hormone Substances 0.000 claims description 19
- 229940088597 hormone Drugs 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 19
- 239000003349 gelling agent Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000004615 ingredient Substances 0.000 claims description 16
- 239000000499 gel Substances 0.000 claims description 14
- 239000004530 micro-emulsion Substances 0.000 claims description 14
- 235000011187 glycerol Nutrition 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- -1 polyoxyethylene nonylphenol Polymers 0.000 claims description 13
- 239000007921 spray Substances 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 10
- 230000001815 facial effect Effects 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 229920001285 xanthan gum Chemical group 0.000 claims description 9
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 108010035532 Collagen Chemical group 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 229920001436 collagen Chemical group 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 6
- 229920002674 hyaluronan Chemical group 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 239000000017 hydrogel Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical group O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 235000021314 Palmitic acid Nutrition 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- UTUUIUQHGDRVPU-UHFFFAOYSA-K aluminum;2-aminoacetate;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Al+3].NCC([O-])=O UTUUIUQHGDRVPU-UHFFFAOYSA-K 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 229960005188 collagen Drugs 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- RNMDNPCBIKJCQP-UHFFFAOYSA-N 5-nonyl-7-oxabicyclo[4.1.0]hepta-1,3,5-trien-2-ol Chemical compound C(CCCCCCCC)C1=C2C(=C(C=C1)O)O2 RNMDNPCBIKJCQP-UHFFFAOYSA-N 0.000 claims description 2
- 241000206575 Chondrus crispus Species 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 230000008595 infiltration Effects 0.000 claims description 2
- 238000001764 infiltration Methods 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 2
- 229920000223 polyglycerol Polymers 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 239000008055 phosphate buffer solution Chemical group 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 41
- 210000004369 blood Anatomy 0.000 abstract description 36
- 208000003251 Pruritus Diseases 0.000 abstract description 15
- 238000002560 therapeutic procedure Methods 0.000 abstract description 11
- 239000004480 active ingredient Substances 0.000 abstract description 8
- 230000007803 itching Effects 0.000 abstract description 6
- 241000721047 Danaus plexippus Species 0.000 abstract description 5
- 230000001575 pathological effect Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 206010067482 No adverse event Diseases 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 63
- 239000007788 liquid Substances 0.000 description 23
- 241001570521 Lonicera periclymenum Species 0.000 description 21
- 239000000523 sample Substances 0.000 description 19
- 239000000284 extract Substances 0.000 description 18
- 238000000034 method Methods 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- 230000003110 anti-inflammatory effect Effects 0.000 description 14
- 239000003862 glucocorticoid Substances 0.000 description 13
- 231100000614 poison Toxicity 0.000 description 13
- 206010033733 Papule Diseases 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 11
- 235000009508 confectionery Nutrition 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 208000009056 telangiectasis Diseases 0.000 description 11
- 206010043189 Telangiectasia Diseases 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 239000002574 poison Substances 0.000 description 10
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 8
- 229940074393 chlorogenic acid Drugs 0.000 description 8
- 235000001368 chlorogenic acid Nutrition 0.000 description 8
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 8
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 8
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000002874 Acne Vulgaris Diseases 0.000 description 7
- 206010000496 acne Diseases 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 102000003777 Interleukin-1 beta Human genes 0.000 description 6
- 108090000193 Interleukin-1 beta Proteins 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 6
- 206010040882 skin lesion Diseases 0.000 description 6
- 231100000444 skin lesion Toxicity 0.000 description 6
- 235000014347 soups Nutrition 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 240000005373 Panax quinquefolius Species 0.000 description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 4
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 235000013532 brandy Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 4
- 235000019410 glycyrrhizin Nutrition 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 3
- 240000000774 Cunila origanoides Species 0.000 description 3
- 235000018274 Cunila origanoides Nutrition 0.000 description 3
- 235000014866 Dictamnus albus Nutrition 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 3
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 3
- 240000005001 Paeonia suffruticosa Species 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000000260 Warts Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001139 anti-pruritic effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 description 3
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000001685 glycyrrhizic acid Substances 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 238000000554 physical therapy Methods 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 235000019605 sweet taste sensations Nutrition 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 235000007586 terpenes Nutrition 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001645380 Bassia scoparia Species 0.000 description 2
- 244000157790 Buglossoides arvense Species 0.000 description 2
- 235000004256 Buglossoides arvense Nutrition 0.000 description 2
- 241000208671 Campanulaceae Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 2
- 244000020518 Carthamus tinctorius Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241001233914 Chelidonium majus Species 0.000 description 2
- 240000005250 Chrysanthemum indicum Species 0.000 description 2
- 241000931705 Cicada Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 244000241872 Lycium chinense Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960004703 clobetasol propionate Drugs 0.000 description 2
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000887 face Anatomy 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000011477 liquorice Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 231100000435 percutaneous penetration Toxicity 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 230000004215 skin function Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 235000001405 Artemisia annua Nutrition 0.000 description 1
- 240000000011 Artemisia annua Species 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 235000011274 Benincasa cerifera Nutrition 0.000 description 1
- 244000036905 Benincasa cerifera Species 0.000 description 1
- 235000016811 Biondella Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241001546929 Campsis grandiflora Species 0.000 description 1
- 241000561734 Celosia cristata Species 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000380450 Danaus melanippus Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000594394 Hedyotis Species 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 244000207740 Lemna minor Species 0.000 description 1
- 235000006439 Lemna minor Nutrition 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000245240 Lonicera Species 0.000 description 1
- 241000218394 Magnolia liliiflora Species 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- XQWFHGOIUZFQPJ-USTPAGJBSA-N Neoisoliquiritigenin Natural products O=C(/C=C/c1ccc(O)cc1)c1c(O)cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O2)cc1 XQWFHGOIUZFQPJ-USTPAGJBSA-N 0.000 description 1
- XQWFHGOIUZFQPJ-LXGDFETPSA-N Neoisoliquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC=C1C(=O)\C=C\C1=CC=C(O)C=C1 XQWFHGOIUZFQPJ-LXGDFETPSA-N 0.000 description 1
- XQWFHGOIUZFQPJ-UHFFFAOYSA-N Neoisoliquiritin Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1O)=CC=C1C(=O)C=CC1=CC=C(O)C=C1 XQWFHGOIUZFQPJ-UHFFFAOYSA-N 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 241001092500 Photinia x fraseri Species 0.000 description 1
- 241000132171 Phryma leptostachya Species 0.000 description 1
- 241001425800 Pipa Species 0.000 description 1
- 241001499733 Plantago asiatica Species 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 240000004064 Poterium sanguisorba Species 0.000 description 1
- 235000008291 Poterium sanguisorba Nutrition 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 235000010674 Prunella vulgaris Nutrition 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 description 1
- 239000000877 Sex Attractant Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241001530209 Swertia Species 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 240000006688 Telosma cordata Species 0.000 description 1
- 235000017352 Telosma cordata Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241001521901 Tribulus lanuginosus Species 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 238000011892 Von Kossa's method Methods 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 1
- 229960000962 bufexamac Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical group C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229940021231 clearskin Drugs 0.000 description 1
- 229960001146 clobetasone Drugs 0.000 description 1
- XXIFVOHLGBURIG-OZCCCYNHSA-N clobetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)CC2=O XXIFVOHLGBURIG-OZCCCYNHSA-N 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- AVEUZYHDYBJRPU-UHFFFAOYSA-N n-(4-ethoxyphenyl)-2-hydroxybenzamide Chemical compound C1=CC(OCC)=CC=C1NC(=O)C1=CC=CC=C1O AVEUZYHDYBJRPU-UHFFFAOYSA-N 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- BCSTWFQGKOAWED-HUCPNFHCSA-N pevisone Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1.C1CC2=CC(=O)C=C[C@]2(C)C2(F)[C@@H]1[C@@H]1C[C@@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O BCSTWFQGKOAWED-HUCPNFHCSA-N 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 206010035114 pityriasis rosea Diseases 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 238000009119 stepdown therapy Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000009333 weeding Methods 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
- 239000009509 xiaoyin Substances 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
- 239000009446 yinchenhao Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提出一种治疗激素依赖性皮炎的中药复方外用制剂,有效部位由以下重量份数的中草药制成:黄精5~80份、金银花5~60份、菊花5~60份、茯苓5~60份、甘草3~60份。还包括制剂的制备方法和应用。本发明重用黄精为君药,金银花和菊花共为臣药,茯苓为佐药,甘草调和全方药性为使药,以滋阴润燥、凉血解毒、清热除湿、祛风止痒为其基本治疗法则,促进激素依赖性皮炎修复。组方简洁、符合治疗激素依赖性皮炎的中医药理论,并有各单味中药的现代药理学成果支撑和佐证;复方有效部位提取工艺简单,效应成分含量高,减少了非有效成分的引入,制剂工艺科学,效应成分在病变组织的透过率高,动物实验及人体试用效果显著,无不良反应,使用方便顺应性好。
Description
技术领域
本发明涉及一种中药复方外用制剂及制备方法和应用,具体涉及一种治疗激素依赖性皮炎的中药复方制剂及其制备方法和应用。
背景技术
激素依赖性皮炎即皮质类固醇激素依赖性皮炎,也称糖皮质激素瘾性皮炎或局部糖皮质激素戒断皮炎,是由于不适当地局部外用糖皮质激素引起的炎症性皮肤病,临床表现为局部逐渐出现表皮萎缩变薄、毛细血管扩张,停用外用激素则出现毛细血管扩张、皮肤菲薄、潮红、水肿、红斑、脱屑、丘疹、痤疮样及酒渣鼻样皮疹等,伴局部刺痛灼痛、瘙痒、干燥、紧绷感等,复用激素时皮损减轻或消退,不断反复。由于各种含糖皮质激素的化妆品和糖皮质激素类药物的滥用,如反复外用皮炎平、派瑞松、倍他米松、氯倍他松等,使激素依赖性皮炎病例数逐年上升,患者多为中青年女性,最常见于面部,且又顽固难治愈,带来各种生理和心理问题,成为皮肤疾病一个棘手的问题,国内有报道糖皮质激素依赖性皮炎目前成为皮肤科门诊第五大疾病,已成为临床医学关注的焦点。
一、西医药治疗现状
糖皮质激素类药物具有强大的抗炎抗免疫反应特性,可抑制很多皮肤病症状,但是在停用激素后2~10天后原有皮损再次出现,甚至加重的现象,即激素的反跳现象。局部长期外用中强效激素,可诱导皮肤结构和功能发生变化,从而使皮肤出现萎缩变薄、毛细血管扩张、多毛、出现萎缩纹、痤疮样丘疹、酒渣鼻样丘疹等不良反应。
西医药主要是针对糖皮质激素依赖性皮炎的具体症状而采用药物和/或物理治疗:(1)激素递减治疗的激素类药物多以效应较弱的激素类药物为主,如地奈德、艾洛松、丁酸氢化可的松等,临床实践证明该方法的效果较差,也逐步被放弃;(2)抗菌药和抗生素类如夫西地酸、红霉素、黄连素、庆大霉素、甲硝唑、莫匹罗星的口服或外用,主要是防治皮肤炎症继发性病源微生物感染;(3)非甾体类抗炎类药物的应用,报道比较多的有氟芬那酸丁酯、吲哚美辛、丁苯羟酸、乙氧苯柳胺等的外用制剂,发挥抑制炎症介质引起的皮肤毛细血管通透性增加,减少炎症渗出,抑制炎性肿胀和炎性增殖过程的肉芽组织增生,并且有抗变态反应作用,主要目的是抗炎止痒;(4)抗组胺药物的应用相对比较普遍,主要有扑尔敏、苯海拉明、赛庚啶、马来酸氯苯那敏、西替利嗪、氯雷他定、咪唑斯汀、氮卓斯汀、依匹斯汀等,发挥抑制组胺、慢反应物质化学介质的释放等变态反应;(5)免疫抑制剂多以他克莫司、吡美莫司软膏等为主,外用可起到局部免疫调节、抗炎及止痒等作用,但不良反应发生率比较高;(6)也有用到重组人表皮生长因子、多磺酸粘多糖、卡介菌多糖核酸、薄芝糖肽、肝素钠等生化药物,还有纳米银、半胱氨酸、维生素、米诺环素、尿素、盐酸利多卡因、硼酸等做成的单一化合物制剂或复方制剂,发挥其相应的药理作用,如促进表皮修复、收敛抗炎、止痒等;(7)物理治疗是除过药物治疗之外的一个比较常用的方法,以各种负离子冷喷和超声雾化给予保水材料或药物促进损伤皮肤修复;采用红蓝光照射、强脉冲光、不同强度激光、磁脉冲、生物共振、液氮冷冻等方法,发挥消炎、减轻疼痛和瘙痒的作用,但对已扩张的毛细血管作用有限;以保湿敷料为主的物理疗法,多以透明质酸、胶原蛋白、黄原胶和植物多糖等大分子保水材料为主,也有用甘油、1,3丁二醇等小分子材料做成敷料,为激素依赖性皮炎提供适合湿度的修复环境,以促进皮肤屏障的修复。(8)此外,心理治疗帮助患者改掉应用激素的心理依赖,使患者具有良好的心态,正确面对皮肤损伤,积极配合治疗。
综上所述,西医治疗以糖皮质激素递减和替代治疗、抗过敏、抗菌抗炎、免疫调节、物理治疗等方法,单独或联合实施,短期内可改善临床症状,但远期疗效尚不理想,易反复发作,且在戒断过程中部分患者易出现反跳现象。
二、中医药治疗现状
近年来中医药防治激素依赖性皮炎呈现广阔前景,不断有新的成果用于临床,目前,中医药学防治激素依赖性皮炎技术路线可分为两类:(1)基于激素依赖性皮炎形成的现代病理学机制的药物筛选和制剂优化。采用单味中草药、有效部位或其中的单体化合物的研究和临床应用,发挥免疫调节、抗炎、保水等作用,主要针对激素依赖性皮炎的皮肤潮红、水肿、红斑、脱屑、丘疹、痤疮样及酒渣鼻样皮疹等症状,以及伴随的局部刺痛灼痛、瘙痒、干燥、紧绷感等,但是对毛细血管扩张、皮肤菲薄核心问题基本没有解决。比较受关注和常用的中草药单体化合物或有效部位有积雪草甘、甘草酸及其衍生物、苦参碱、薄荷脑、茯苓提取物、青刺果提取物、芍药总苷、雷公藤多甙、原花青素低聚体、鞣酸等,单独使用或者联合其他化学成分形成复方制剂,主要是发挥抗炎、免疫调节等药理作用,辅助皮肤屏障功能恢复。上述研究和治疗模式以及这些中草药提取物的应用方法类似与化学药物,不具备中医关于激素依赖性皮炎发病理论和中药的配伍理论,单一的化学药物、中药单体或单味中药很难达到理想的临床效果,甚至不排除不可避免的不良反应。(2)基于传统中医药的病机理论和药物配伍理论的研究模式。糖皮质激素类药物是近代用于临床的药物,按照现代药理学理论激素依赖性皮炎应该属于糖皮质激素类药物的不良反应。传统中医药对激素依赖性皮炎没有记载。现代中药医普遍的共识是把激素依赖性皮炎归为中医“热毒”的范畴。目前普遍共识认为激素类药物味辛性燥甘温之品,应用于肌肤则易导致肌肤为外感毒热,使用日久热邪毒壅于肌肤,助阳化热,日久灼盛,热毒灼伤血络,发于肌肤则为皮肤受损、表皮菲薄潮红、毛细血管扩张、水肿、红斑、脱屑、丘疹、痤疮样及酒渣鼻样皮疹;热灼阴液,营血耗散,肌肤失于濡养则皮肤干燥、脱屑,并有紧绷感。其病因病机多可归纳为外感热药毒与血热内蕴相合,风、热、湿、毒壅滞于肌肤,肌肤气血失和。治疗依据病因、病机,主要以滋阴润燥、凉血解毒、清热除湿、祛风止痒为其基本治疗法则。也有部分医家在基本治疗法则基础上有着不同的看法:①认为本病最为贴切的名称应为再生性皮炎、红脸疫,因药毒为患、脾虚禀赋不耐,不能达邪外出所发,同时伴有心火血热识盛,阴液耗伤,治疗应以扶正、祛邪为主,多从健脾除湿、清热解毒、祛风止痒论治。②有根据中医“壮火食气”的理论,认为大剂量或长期使用糖皮质激素易损伤人体阳气,或过用苦寒伤阳之品或素体阳气虚弱,加之外感湿毒,阳虚失运化则气血瘀滞、湿邪蕴于腠理。病本为阳虚,标为湿浊、血瘀、表郁等。治疗上注重顾护人体阳气,以温阳扶正为基本治疗原则。③有认为本病缠绵难愈、愈后复发的根本原因是气血瘀滞、毒邪不能透泄,不应过度使用寒凉药物,治宜使气血流通、汗孔开阖,驱邪外出,采用一凉一热、一开一阖,以清热解毒、活血化瘀为法。
尽管中医药对糖皮质激素类的基本观点是“药毒”范畴,但是临床治疗依然处于探索阶段,临床用药就各有长短。经典处方主要有凉血五花汤(玫瑰花、野菊花、鸡冠花、红花、凌霄花)配伍理气活血之药内服;将六味地黄丸和逍遥丸化裁成六味地黄汤内服;辛凉平剂银翘汤加减(银花、连翘、辛夷、桔梗等);《医宗金鉴·外科心法要诀》枇杷清肺饮加减,方中枇杷叶、桑白皮可清泻肺热,黄连、黄柏解毒除湿,丹参凉血活血,野菊花、金银花药性轻清透表,共奏清肺、凉血、解毒之功。《温病条辨》中的青蒿鳖甲汤以滋阴清热透邪;张仲景《伤寒论》白通汤等;茵陈蒿汤配伍止痒解毒之药;清胃散加蝉蜕。
从五脏论治激素依赖性皮炎以“肺主皮毛”为主导,以清肺解毒,凉血止痒为基本治法,分别采用清肺解毒饮、清肺康肤合剂及枇杷清肺饮为基础方治疗,3方均配伍桑白皮、银花、连翘、地丁以清泄肺胃之热;也有从心论治采用消风散加减口服。
基于滋阴润燥,养阴清热方治疗阴虚内热型激素皮炎患者,皮损潮红、瘙痒明显减轻,脱屑减少,其主要方药为北沙参、玄参、生地、地骨皮、牡丹皮、赤芍、夏枯草、蛇舌草白鲜皮、地肤子、生甘草等,若皮质损而鲜红可加黄苓、马齿觅各,若皮肤纤薄见血丝,可加丹参、鸡血藤,若多有脓包加野菊花,瘙痒甚剧加灵磁石、龙骨等;也有认为邪热日久可耗气伤血,方中重用制首乌、鸡血藤、川芎、熟地等大量滋阴润燥之药,配伍丹参、刺蒺藜、浮萍等走散之品,润而不燥、补而不滞,并可透表止痒,加用何首乌、当归等中草药煎汤湿敷,具有养血润肤的功效,明显优于西医对照组。
基于活血化瘀对于面部毛细血管扩张明显者多运用三棱、莪术等活血化瘀药,以紫草、牡丹皮为主取其凉血、活血之功。
基于凉血祛风,以凉血化斑、补养气血、滋阴润肤为主,常用方如凉血消风散,也有自拟方取得较好的疗效,如解毒靓颜汤(生地、丹皮、赤芍、白茅根、黄芩等)配合中药药液湿敷。
基于解毒除湿采用由龙胆草、车前草、白茅根、大青叶、生地、黄芩、滑石粉组成的清热除湿汤,自拟清热利湿汤方,以清热解毒之菊花、金银花、槐花配伍健脾利湿之茯苓、薏苡仁。
基于内外热邪相搏结的理论,认为激素依赖性皮炎正是由于机体素有蕴热,皮肤再接触火热之品激素,内外热邪相结蕴于肌肤而发。有中医药工作者拟定了白虎清皮饮,方中选白虎汤中主要药物石膏、知母为君,取其清气分热,泻肺胃之火之功;白茅根、紫草、金银花、生地黄、牡丹皮等清热凉血之品为臣药,白茅根与生地黄又有滋阴之功效;“伤于头面者多风温、风热”故采用徐长卿、薄荷祛风止痒,现代药理研究显示,徐长卿有抗过敏作用;砂仁化湿、行气、温中,以防寒凉伤胃;桔梗载药上行共为佐药;甘草调和诸药。诸药共奏,清泻肺胃热邪、凉血滋阴之功效。也有类似自拟中药方(胆草、黄芩、栀子、生地、丹皮、白鲜皮、白茅根、茯苓、冬瓜皮、生白术、车前子、泽泻、野菊花等),并根据患者具体情况随证加减,如舌尖红苔白腻,内热较盛者加羚羊角粉冲服;伴有局部微血管扩张、红斑或潮红水肿者,加青蒿、赤芍、地骨皮等;灼热疼痛伴局部有丘疹、脓疱或痤疮者,加金银花、连翘等。具有清热凉血、养血润燥、祛风止痒功能的消银颗粒(地黄、丹皮、赤芍、当归、苦参、银花、玄参、牛蒡子、蝉蜕、白鲜皮、红花、大青叶、防风等组成)也有用于激素依赖性皮炎的治疗。
以中医药理论为基础的中药外治也是一个非常重要的途径。如复方黄柏液(黄柏、连翘、金银花、蜈蚣、蒲公英等),具有清热解毒、燥湿、消肿祛腐的功效,可改善炎性丘疹和脓疱,对毛细血管扩张、色素沉着和皮肤萎缩也有一定的效果,但是很多患者的皮肤不能长期耐受。将不灰木与含有蛇床子、地肤子、苦参、冰片的中药药液共同煨炙,采用石疗法;应用由防风、艾叶、透骨草、羌活、独活、马齿觅、地榆等配伍组成的复方中药煎汤冷却湿敷的方法,具有清热解毒,凉血止痒的功效;将黄柏、苦参、板蓝根、防风、公英配伍组成治疗小儿激素皮炎的外洗方,使患儿易于接受,且吸收迅速,安全便捷等等。也有中西药物配合用于临床治疗,既可改善激素依赖性皮炎的症状,又促进损伤部位皮肤的修复,使中药复方有效成分充分进入细胞内发挥作用,取得较好的疗效。
综上所述,目前临床治疗激素依赖性皮炎的中药复方,无论是口服还是外用,多以滋阴凉血清热解毒类的寒凉药物为主,但长期服用,及易影响胃肠道及其他脏器的功能,甚至导致不可逆的药物性脏器损伤;现有中药复方外用制剂的制备技术和工艺,如传统的水提浓缩、醇提、油浸油炸等技术制备的水剂、酊剂、糊剂或膏剂,制剂中的效应成分含量低,皮肤刺激性大,有效成分渗透率低,很难能达到有效的治疗浓度。
本发明的中药复方以滋阴润燥为主,辅助以清热解毒祛风,分离提纯有效部位或效应成分,所制备外用制剂释放效应成分平稳,效应成分皮肤透过率高直达病所,能有效控制激素依赖性皮炎的发展,促进损伤皮肤修复愈合,而且便于使用,患者的顺应性高。
发明内容
本发明的目的是提出一种安全、高效、临床上应用方便的治疗激素依赖性皮炎的中药复方外用制剂及其制备方法和应用。
本发明的技术方案为:
所述一种治疗激素依赖性皮炎的中药复方外用制剂,其特征在于:中药复方提取的有效部位由以下重量份数的中草药制成:黄精5~80份(优选10~70份,更优选15~70份,最优选20~50份)、金银花5~60份(优选10~50份,更优选15~50份,最优选15~30份)、菊花5~60份(优选10~50份,更优选15~50份,最优选15~30份)、茯苓5~60份(优选10~60份,更优选15~60份,最优选15~30份)、甘草3~60份(优选5~30份,更优选5~25份,最优选5~20份)。
进一步,所述复方外用制剂的剂型为乳剂、乳膏剂、凝胶剂、喷雾剂、医用敷料、贴剂或面膜。
进一步,所述复方外用制剂的乳剂和乳膏剂为O/W型乳膏剂;所述凝胶剂为水凝胶、脂质体凝胶;所述喷雾剂为水凝胶溶液、O/W型微乳喷雾剂;所述医用敷料为溶液剂、凝胶剂、O/W型微乳浸润的医用敷料;所述贴剂为水凝胶贴剂、乳胶贴剂;所述面膜为溶液剂、凝胶剂、O/W型微乳浸润的面膜。
进一步,所述复方外用制剂由所述有效部位和药用辅料组成,其中中药复方提取的有效部位占0.2%~50%,药用辅料占50%~99.8%,以质量百分比计。
进一步,所述药用辅料中,O/W乳膏剂基质辅料由液体石蜡、十六醇、十八醇、三乙醇胺、丙二醇、十二烷基硫酸钠、平平加O、甘油、乳化剂OP、单硬脂酸甘油酯、聚乙二醇-7-甘油辛酸(TEFOSE 63)、葵酸酯(Labrasol)中两种以上成分的混合物及纯化水组成;O/W型微乳喷雾剂中的乳化剂选自一种或两种HLB值为5~19的非离子表面活性剂,助乳化剂选自丙二醇、丙三醇、聚甘油酯中的一种或多种,油相为肉豆蔻酸异丙酯、单亚油酸甘油酯、油酸乙酯、维生素E及其酯、棕榈酸或多种长链脂肪酸油混合物;凝胶剂的辅料由卡波姆或透明质酸或胶原蛋白或黄原胶,以及甘油、三乙醇胺、磷酸盐缓冲液组成;贴剂的骨架材料选用聚丙烯酸钠,交联剂选用甘羟铝和酒石酸,增稠剂选用羧甲基纤维素钠或黄原胶,保湿剂选用卡波姆、透明质酸、胶原蛋白、卡拉胶、黄原胶、甘油、丙二醇、丁二醇或聚乙二醇。
本发明组方及其制剂所治疗激素依赖性皮炎,按照现代药理学理论激素依赖性皮炎应该属于糖皮质激素类药物的不良反应,现代中药医理论把激素依赖性皮炎归为中医“药毒”的范畴。激素类药物属辛燥甘温之品,为外感毒热,使用日久邪毒壅于肌肤,易助阳化热,积久灼盛,迫血妄行,发于肌肤则为皮肤潮红、水肿、红斑、脱屑、丘疹、痤疮样及酒渣鼻样皮疹、毛细血管扩张;热灼阴液,营血耗散,肌肤失于濡养则皮肤干燥、脱屑,并有紧绷感。肌肤灼伤,卫外失职,风湿相兼侵袭,则皮损缠绵难愈。其病因病机多可归纳为外感热(药)毒与血热内蕴相合,风、热、湿、毒壅滞于肌肤,肌肤气血失和。治疗依据病因、病机,主要以滋阴润燥、凉血解毒、清热除湿、祛风止痒为其基本治疗法则。
本发明组方中,重用黄精为君药,其性平味甘,归脾、肺、肾经,具有补气养阴、健脾、润肺、益肾的作用。《圣济总录》记载黄精善治大风癞疮,即治疗“营气不清,久风入脉,因而成癞,鼻坏色败、皮肤痒溃”。方中重用黄精,滋阴润燥、丰肌体、泽皮肤。金银花性寒,味甘,入肺、心、胃经,《神农本草经》载:“金银花具有清热解毒、凉血化淤之功效,主治外感风热、瘟病初起、疮疡疔毒、红肿热痛”等,《名医别录》中被列为上品;菊花性微寒,味微辛、甘、苦,归肺、肝经,能疏散风热,清肝明目等作用。《本草经疏》:“菊花专制风木,故为去风之要药。苦可泄热,甘能益血,甘可解毒,平则兼辛,故亦散结,其主风头眩、肿痛、皮肤死肌、恶风、湿痹。生捣最治疔疮,血线疔尤为要药,疔者风火之毒也。”金银花、菊花二药合用作为臣药,共奏清热解毒,凉血化瘀祛风的作用,以助君药黄精养阴之力。茯苓性平味甘、淡,归心、肺、脾、肾经。《用药心法》:“茯苓,淡能利窍,除湿之圣药也。味甘平补阳,益脾逐水,生津导气。”《补缺肘后方》:“治皯,白蜜和茯苓涂上,满七日。”在本方中茯苓甘淡健脾健肌肤,除湿毒。甘草味甘性平,归心、肺、脾胃经,具有调和诸药等作用外,还可补脾益气,缓急止痛,润肺,生品药性微寒可清热解毒,用于热毒疮疡,《外科十法》记载菊花甘草汤用于治疔。
现代药理学研究表明,黄精主要活性成分为甾体皂苷类化合物和甘露糖等,在抗氧化、抗疲劳、延缓衰老、抗病原微生物、抗病毒等方面具有显著作用;金银花含有木樨草素、肌醇、皂苷、绿原酸和异绿原酸等成分,具有抗病原微生物作用、抗炎和解热作用、加强免疫机能作用、抗内毒素等作用。金银花有效成分木犀草素能够通过抑制MMP-1基因和蛋白表达从而降低胶原蛋白的分解来保护皮肤,可能成为是一种有效的抗皮肤光老化治疗剂;金银花煎液外敷治疗西妥昔单抗致痤疮样皮疹。菊花主要含有黄酮类、黄酮醇类和二氢黄酮类及其苷类,萜类皂苷,绿原酸和咖啡酸等酸类成分,具有保护心血管、免疫调节、抑菌、抗肿瘤、保护红细胞膜、抗疲劳、镇痛、调血脂和促进神经生长作用。茯苓主要含有多糖、三萜、脂肪酸、甾醇、酶等,茯苓有多种药理作用,其中起主要作用的是茯苓多糖和茯苓三萜类化合物,茯苓多糖具有抗肿瘤、保肝、利尿、抗衰老、抗炎、降血脂、增强免疫、催眠等作用,茯苓三萜具有抗肿瘤、保肝、抗衰老、抗炎、增强免疫等作用。茯苓提取物能明显延缓大鼠皮肤衰老,抑制酪氨酸酶基因表达和酶活性使黑素细胞和黑素颗粒减少。甘草含有甘草素、异甘草素和新异甘草苷等黄酮类化合物,有明显的抗溃疡、抗菌、抗炎、降血脂等药用功能,另外,甘草可以润滑皮肤,为众多国内外高档化妆品抗炎和抗过敏剂;甘草酸、甘草次酸等三萜皂苷类化合物,具有保肝降酶、抗菌、抗病毒抗炎和免疫调节效应等;甘草多糖具有显著的抗病毒和提高免疫力的作用。近年来临床上正在试用甘草及其有效成分的制剂治疗各种皮肤病,包括过敏性紫癜、银屑病、湿疹、玫瑰糠疹、荨麻疹、系统性红斑狼疮、小儿丘疹性肢端皮炎样皮疹、带状疱疹、扁平疣、斑秃、白癜风和皮肤色素沉着等。甘草提取物及其黄酮类化合物、甘草酸等对变态反应性皮肤病、皮肤肿瘤、病毒性皮肤病、色素沉着等皮肤病均具有显著疗效。以上所述现代药理研究成果为该复方药理学作用提供了佐证。
本发明进一步解决其技术问题采用的技术方案:一种治疗激素依赖性皮炎的中药复方外用制剂的制备方法,所述有效部位的制备包括以下步骤:
(1)将处方量的黄精、茯苓、甘草碎成5~60目粉末,采用3~20倍量10%~95%乙醇回流提取3~5次,回收乙醇,低温减压浓缩,脱色,柱层析分离所需成分;或将处方量的黄精、茯苓、甘草用3~20倍量水,煎煮3~5次,分离煎煮液,低温减压浓缩至比重1.05~1.20,加医用乙醇至乙醇浓度为20%~85%,搅拌,静置或离心,取上清液脱色,回收乙醇后层析柱分离所需成分;获得有效部位或有效成分A;
(2)将处方量的金银花和菊花用3~20倍量10%~95%乙醇有机溶剂回流提取3~5次,回收乙醇,低温减压浓缩,脱色,柱层析分离所需成分;或将处方量的金银花和菊花用3~20倍量水,煎煮提取3~5次,分离煎煮液,低温减压浓缩至比重1.05~1.20,加医用乙醇至乙醇浓度为20%~85%,脱色,回收乙醇后柱层析分离所需成分,获得有效部位B;
(3)合并有效部位A、B,即得中药复方提取的有效部位或有效成分。
有益效果
本发明是基于中医对激素依赖性皮炎的整体认识和现代病理学对激素依赖性皮炎形成机制的研究结果,结合现有技术和多年临床经验,充分发挥中药复方制剂现代化技术的成果。本发明中药复方虽与现有技术中个别单味药有相同或相似之处,但君臣佐使无雷同,重用黄精,辅以金银花和菊花清热解毒祛风、茯苓祛湿和甘草调和药性,每味药的用量不同,效应有别,是在前人治疗方剂基础上的推陈出新,君臣佐使配伍清晰,组方简洁,性味平和,凉而不滞,符合中医药理论,又得以现代药理学的佐证。基础研究显示,中药复方外用制剂中的效应成分具有良好的皮肤组织透过性。全方具有补气养阴润燥,清热解毒祛风,凉血消肿止痛的作用,临床施用发现,起效迅速,效果良好,有效治疗激素依赖性皮炎患者的皮肤干燥、热感、痒感、皮肤发红起痘以及敏感等症状,抑制激素依赖性皮炎的发展,促进激素依赖性皮炎处皮肤功能的恢复;其次,复方所用中药均为常用中药,市场供应充足,价格低廉;再次,本发明中药复方外用制剂提取工艺简单,效应成分含量高,减少了非有效成分的引入,制剂工艺科学,效应成分在病变组织的透过率高,动物实验及人体试用效果显著,无不良反应。
综上所述,以本发明中药复方为基础,采用现代工艺高效提取复方中有效部位,并将其制备成适合于治疗激素依赖性皮炎的剂型,生产过程环境友好,产品质量稳定,成本低廉,制剂药效显著,未发现毒副作用,患者使用方便且顺应性高,具有良好的经济效益和社会效益。
本发明的附加方面和优点将在下面的描述中部分给出,部分将从下面的描述中变得明显,或通过本发明的实践了解到。
附图说明
本发明的上述和/或附加的方面和优点从结合下面附图对实施例的描述中将变得明显和容易理解,其中:
图1:绿原酸和薯蓣皂苷离体SD大鼠皮肤Qn-T曲线图。
图2:中药复方提取物凝胶和阳性对照药对豚鼠激素依赖性皮炎皮肤组织病理影响;注:A:皮肤组织HE染色结果 B:皮肤组织硝酸银染色结果;1:空白组 2:模型组 3:空白基质组 4:低剂量组 5:中剂量组 6:高剂量组 7:阳性对照药。
图3:中药复方提取物凝胶和阳性对照药对豚鼠激素依赖性皮炎血清中IgE水平的影响;注:与对照组比较,*P<0.05;与模型组比较,#P<0.05;A:正常组 B:模型组 C:空白基质组 D:低剂量组 E:中剂量组 F:高剂量组 G:对照组。
图4:中药复方提取物凝胶和阳性对照药对豚鼠激素依赖性皮炎血清中IL-1β、IL-6、G-CSF、TNF-α水平的影响;注:A:正常组 B:模型组 C:空白基质组 D:低剂量组 E:中剂量组 F:高剂量组 G:对照组。
具体实施方式
下面详细描述本发明的实施例,所述实施例是示例性的,旨在用于解释本发明,而不能理解为对本发明的限制。
实施例1:中药复方有效部位的制备
(1)取黄精60g、茯苓30g、甘草20g碎成40目粉末,加10倍量85%乙醇回流提取3~5次,每次2小时,分离提取液,低温减压回收乙醇后活性炭脱色,过滤分离液体上离子交换柱进行分离,接收分离液浓缩至比重1.2。获得有效部位A,备用。
(2)取金银花30g、菊花30g,加10倍量85%乙醇,回流提取3~5次,每次1小时,分离提取液,低温减压回收乙醇后活性炭脱色,过滤分离液体上离子交换柱进行分离,接收分离液浓缩至比重1.2。获得有效部位B,备用。
(3)合并有效部位A、B,即得中药复方的有效部位。
实施例2:中药复方有效部位的制备
(1)取黄精60g、茯苓35g、甘草30g,加12倍量水,煎煮3次,每次2小时,分离煎煮液,浓缩至比重1.12,迅速搅拌,加入医用乙醇至乙醇浓度为85%,混合液体静置4小时,过滤分离上清液回收乙醇后,加入药材等量活性炭搅拌2小时,过滤去除活性炭,液体上离子交换柱分离,分离所得液体浓缩至比重1.2。获得有效部位A。
(2)取金银花35g、菊花35g,加10倍量水,煎煮3次,每次1小时,分离煎煮液,浓缩至比重1.12,迅速搅拌,加入医用乙醇至乙醇浓度为85%,混合液体静置4小时,过滤分离上清液回收乙醇后,加入药材等量活性炭搅拌2小时,过滤去除活性炭,分离所得液体浓缩至比重1.2。获得有效部位B。
(3)合并有效部位A、B,即得中药复方提取的有效部位。
实施例3:有效部位浸膏的制备
取黄精60g、茯苓35g、金银花35g、菊花35g,甘草15g,黄精、茯苓和甘草粉碎成40目与其他药材混合,加15倍量85%乙醇,浸泡12小时,缓慢放出浸提液。相同方法浸提4次,合并浸提液,低温减压蒸馏回收乙醇,活性炭脱色后上交换柱分离,分离液浓缩至比重1.2.即得中药复方有效成分浸膏。
实施例4:O/W乳膏的制备
称取TEFOSE 63 8.0克、Labrasol 2.0克、单硬脂酸甘油酯3.0克、十六醇和十八醇1.5克、乳木果油10克置容器内,80℃水浴加热至完全融化,保温,得油相;取实施例3提取的中药复方有效成分20.0克和丙二醇5克,加入80℃纯水50.5克,搅拌均匀,得水相B;将油相A加入水相B,边加边搅拌;加完后继续搅拌30分钟,冷却即得含15.0%中药复方效应成分的O/W型乳膏剂。
实施例5:凝胶的制备
称取5.0克透明质酸、6克甘油和4克丙二醇,混合,加入适量纯水,充分搅拌,至透明质酸完全溶胀;另取实施例2中药组方提取的有效部位10g和3克二乙二醇单乙基醚充分混合,加入透明质酸胶体溶液中,充分搅拌成均一体系,即得含中药复方有效成分10.0%的凝胶剂。
实施例6:凝胶的制备
称取1.0g卡波姆940、0.2克黄原胶、5克甘油、5克丙二醇混匀,加入纯水充分搅拌至卡波姆和黄原胶完全溶胀,滴加三乙醇胺调整pH为5.5~6.5。取实施例1中药组方提取的有效部位10克,加到溶胀好的凝胶基质中,最后加纯水至100克,搅匀,即得含中药复方10.0%的凝胶剂。
实施例7:O/W型微乳喷雾剂、O/W型微乳医用敷料的制备
精密称取25g乳化剂二乙二醇单乙基醚或油酸聚乙二醇甘油酯和8g助乳化剂丙二醇混匀备用;另取1.5g油相肉豆蔻酸异丙酯或棕榈酸或油酸乙酯或单甘油酸甘油酯,5.0g实施例2中药组方提取的有效部位,搅拌下缓慢滴加到上述乳化剂和助乳化剂的混合物中,再缓慢加入纯化水至100g,将其在高压均质机上800bar压力下循环8次,或用匀浆机高速搅拌30min,即得含15.0%的O/W型微乳。
将上述制备的O/W型微乳分装于不透光按压式喷雾瓶中即得O/W型微乳喷雾剂。
将上述制备的O/W型微乳吸附于医用棉纱或纱布、或医用无纺布上,密封包装即为O/W型微乳医用敷料。
实施例8:贴剂的制备
将50g聚丙烯酸钠NP-700,1.0g甘羟铝和2.0g酒石酸加入到50g甘油中,磁力搅拌器搅匀后作为I相备用;取2g羧甲基纤维素钠用20mL纯化水使其充分溶胀,搅拌均匀加入I相搅拌均匀,作为II相;另取5g卡波姆940用50mL纯化水使其充分溶胀,搅拌均匀加入II相,搅拌均匀,得到空白基质,加入实施例3复方效应成分20g,搅拌均匀,用三乙醇胺调pH5.5~6.5,即得加药基质,在水浴加热条件下搅拌炼和,均匀涂布于无纺纱布上即得到含复方有效部位10%的贴剂。
实施例9:中药复方制剂的体外透皮及药效学实验
一、O/W乳膏剂体外透皮实验
1、透皮吸收实验
用电推剪剪去SD大鼠腹部毛,乙醚麻醉脱颈处死,手术剥离剑突以下腹部去毛皮肤,剔除皮下黏膜和脂肪组织,用生理盐水冲洗干净,滤纸吸干皮肤表面生理盐水,得实验用新鲜全皮,备用。
将制备好的SD大鼠皮肤剪成大小适宜的6块,分别固定在6个Franz扩散池的供药池和接受池之间,皮肤角质层面向供药池。皮肤真皮一侧与接收液接触,排净气泡,接收液为30%乙醇-生理盐水,Franz扩散池外(37±0.5)℃水浴循环,接收池内300rpm恒速搅拌。温度恒定后,1个供药池轻轻注入30%乙醇-生理盐水,另外5个供药池加入含15.0%中药复方有效成分的凝胶剂2克。
恒速搅拌并开始记时,分别在开始后0.5、1、2、4、6、8、12h从取样管抽取接收液1.0mL,置于具塞试管中,每次取样后均补加1.0mL等温接收液并排除接收池中的气泡。取出的1.0mL样液经微孔滤膜过滤后进样分析,空白皮肤作为测定的空白对照。采用高效液相色谱法测定样品中绿原酸的含量作为透皮吸收的考察指标。
1)体外透皮实验结果:
按下式计算绿原酸和薯蓣皂苷的单位面积累计透过量(Qn)
式中,Cn为第n个取样点测得的药物浓度(μg·ml-1);V为接收液体积(17mL);Ci为第i个取样点测得的药物浓度(μg·ml-1);Vi为取样体积(1.0mL);A为渗透面积(1.67cm2),结果见图1。
2)绿原酸和薯蓣皂苷的透皮吸收参数:
以绿原酸的累积渗透量(Qn)分别对时间t进行线性回归,所得方程即为Higuchi方程,所得斜率K即为藁苯内酯的透皮速率常数Jss(μg·cm-2·h-1),见表1:
表1绿原酸和薯蓣皂苷的Higuchi方程及透皮速率常数
由图1和表1可知,制备的凝胶剂中效应成分绿原酸具有良好的皮肤组织透过性。
2、中药复方提取物凝胶剂的药效学实验
免疫球蛋白E(Ig E)(武汉基因美科技有限公司)、豚鼠白细胞介素1β(IL-1β)(武汉基因美科技有限公司)、白细胞介素6(IL-6)(武汉基因美科技有限公司)、粒细胞集落刺激因子(G-CSF)(武汉基因美科技有限公司)、肿瘤坏死因子α(TNF-α)(武汉基因美科技有限公司);钙盐染色试剂盒(Von Kossa法)(北京索莱宝科技有限公司);他克莫司软膏(安斯泰来制药中国有限公司生产,批号:J20140147,规格:10g:0.03%);丙酸氯倍他索标准品(中国食品药品检定研究院)。
1)激素依赖性皮炎动物模型的建立及动物分组和药物干预
造模:56只豚鼠实验前在动物房适应性饲养7天后开始实验,自由饮食和进食。于背部左右两侧对称部位选3cm×3cm区域剃毛,随机抽取48只用于激素依赖性皮炎模型建立。用含0.05%丙酸氯倍他索酊剂均匀涂于背部一侧,另一侧用75%酒精涂抹作为自身对照。剩余8只在背部一侧涂抹75%酒精做空白对照。每天涂药2次,连续使用15天,用药过程中观察皮肤变化。
分组:48只豚鼠造模成功7天后,随机分6组,每组8只。模型组给予生理盐水、空白基质组给予空白凝胶、低剂量组给予1.5%(按药材含量计算)凝胶剂、中剂量组给予3.0%(按药材含量计算)凝胶剂、高剂量组给予6.0%(按药材含量计算)凝胶剂,对照组给予他克莫司软膏。剩余8只作为正常对照组。每日涂药2次,连续涂药15天。
样本采集及检测:观察用药过程中局部皮肤变化,并于给药结束后心脏取血3-4ml检测血中IgE、IL-1β、IL-6、G-CSF、TNF-α。同时处死并分别取背部用药区及对照区皮肤肉眼观察并做病理切片,经HE染色和硝酸银染色后,镜下观察皮肤各层细胞及附件的变化情况。
2)结果
一般情况观察:造模给药15天,停药3天后,豚鼠造模部位皮肤出现红斑丘疹、肿胀、毛细血管扩张现象,证明造模成功。造模后给药治疗15天肉眼观察可见参花凝胶低剂量组皮损可见部分红斑丘疹,毛细血管扩张存在,中剂量组皮损有好转,高剂量组以及阳性对照组红斑丘疹基本消退,无毛细血管扩张现象。
皮肤组织病理学变化:皮肤组织HE染色和von kossa/硝酸银染色病理结果如图2显示,模型组皮肤真皮层(箭头所指处)中,乳头层和网织层排列最紊乱,炎症部位最多。空白基质组损伤程度与模型组类似,炎症部位减少。参花凝胶低剂量和中剂量组损伤程度减少,网织层(箭头所指处)紊乱,炎症部位(箭头所指处)减少。参花凝胶高剂量组和阳性对照药组皮肤组织略微紊乱,表皮无明显损伤,炎症几乎没有。
血清中IgE的变化:如图3所示,与正常组相比,模型组豚鼠血清中IgE水平明显升高,差异有统计学意义(P<0.05),提示激素依赖性皮炎模型造模成功。与模型组比较,中药复方提取物凝胶低剂量组、中剂量组、高剂量组、对照组血清IgE明显降低,并且中药复方提取物凝胶高剂量组与模型组比较差异有统计学意义(P<0.05);高剂量组与阳性对照组血清IgE比较无显著差异(P>0.05)。
血清中IL-1β、IL-6、G-CSF、TNF-α的变化:如图4所示,由于激素依赖性皮炎是糖皮质激素类药物引起的皮肤损伤,该类药物自身具有抗炎作用,对多种炎症因子具有抑制作用,因此,各组炎症因子IL-1β、IL-6、G-CSF、TNF-α含量没有明显变化,无统计学意义。
3)结论
以上结果表明本发明的中药复方提取物凝胶对豚鼠激素依赖性皮炎有缓解作用和治疗作用。
实施例10:面部激素依赖性皮炎志愿者使用本发明中药复方贴敷剂效果观察
某女,25岁,曾使用某品牌护肤品7天后感觉面部皮肤干燥伴发热,可观察到面部皮肤病理性发红,3天后面部开始出现丘疹,毛细血管扩张,皮肤菲薄,局部有组织液渗出。之前所用的护肤品使用后症状加重。后发现所用护肤品含有糖皮质激素类药物成分。确诊为激素依赖性皮炎。
志愿使用本发明的中药复方提取物制备的参花面膜,每天早晚各贴敷一次,5天后症状缓解,10天后减为每天贴敷一次,20天后症状消除,随后隔天贴敷一次,配合使用安全护肤品,再无复发。
尽管上面已经示出和描述了本发明的实施例,可以理解的是,上述实施例是示例性的,不能理解为对本发明的限制,本领域的普通技术人员在不脱离本发明的原理和宗旨的情况下在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。
Claims (10)
1.一种治疗激素依赖性皮炎的中药复方外用制剂,其特征在于:中药复方提取的有效部位由以下重量份数的中草药制成:黄精5~80份、金银花5~60份、菊花5~60份、茯苓5~60份、甘草3~60份。
2.根据权利要求1所述一种治疗激素依赖性皮炎的中药复方外用制剂,其特征在于:中药复方提取的有效部位由以下重量份数的中草药制成:黄精10~70份、金银花10~50份、菊花10~50份、茯苓10~60份、甘草5~30份。
3.根据权利要求2所述一种治疗激素依赖性皮炎的中药复方外用制剂,其特征在于:中药复方提取的有效部位由以下重量份数的中草药制成:黄精15~70份、金银花15~50份、菊花15~50份、茯苓15~60份、甘草5~25份。
4.根据权利要求3所述一种治疗激素依赖性皮炎的中药复方外用制剂,其特征在于:中药复方提取的有效部位由以下重量份数的中草药制成:黄精20~50份、金银花15~30份、菊花15~30份、茯苓15~30份、甘草5~20份。
5.根据权利要求1~4所述一种治疗激素依赖性皮炎的中药复方外用制剂,其特征在于:所述复方外用制剂的剂型为乳剂、乳膏剂、凝胶剂、喷雾剂、医用敷料、贴剂或面膜。
6.根据权利要求5所述一种治疗激素依赖性皮炎的中药复方外用制剂,其特征在于:所述复方外用制剂的乳剂和乳膏剂为O/W型乳膏剂;所述凝胶剂为水凝胶、脂质体凝胶;所述喷雾剂为水凝胶溶液、O/W型微乳喷雾剂;所述医用敷料为溶液剂、凝胶剂、O/W型微乳浸润的医用敷料;所述贴剂为水凝胶贴剂、乳胶贴剂;所述面膜为溶液剂、凝胶剂、O/W型微乳浸润的面膜。
7.根据权利要求5所述一种治疗激素依赖性皮炎的中药复方外用制剂,其特征在于:所述复方外用制剂由所述中药复方提取的有效部位和药用辅料组成,其中中药复方提取的有效部位占0.2%~50%,药用辅料占50%~99.8%,以质量百分比计。
8.根据权利要求7所述一种治疗激素依赖性皮炎的中药复方外用制剂,其特征在于:所述药用辅料中:
O/W乳膏剂基质辅料由液体石蜡、十六醇、十八醇、三乙醇胺、丙二醇、十二烷基硫酸钠、平平加O、甘油、乳化剂OP、单硬脂酸甘油酯、聚乙二醇-7-甘油辛酸、葵酸酯中两种以上成分的混合物及纯化水组成;
O/W型微乳喷雾剂中的乳化剂选自一种或两种HLB值为5~19的非离子表面活性剂,助乳化剂选自丙二醇、丙三醇、聚甘油酯中的一种或多种,油相为肉豆蔻酸异丙酯、单亚油酸甘油酯、油酸乙酯、维生素E及其酯、棕榈酸或多种长链脂肪酸油混合物;
凝胶剂的辅料由卡波姆或透明质酸或胶原蛋白或黄原胶,以及甘油、三乙醇胺、磷酸盐缓冲液组成;
贴剂的骨架材料选用聚丙烯酸钠,交联剂选用甘羟铝和酒石酸,增稠剂选用羧甲基纤维素钠或黄原胶,保湿剂选用卡波姆、透明质酸、胶原蛋白、卡拉胶、黄原胶、甘油、丙二醇、丁二醇或聚乙二醇。
9.一种权利要求1~8所述治疗激素依赖性皮炎的中药复方外用制剂的制备方法,其特征在于:所述中药复方有效部位的制备方法包括以下步骤:
步骤1:将处方量的黄精、茯苓、甘草碎成5~60目粉末,采用3~20倍量10%~95%乙醇回流提取3~5次,回收乙醇,低温减压浓缩,脱色,柱层析分离所需成分,获得有效部位A;或将处方量的黄精、茯苓、甘草用3~20倍量水,煎煮3~5次,分离煎煮液,低温减压浓缩至比重1.05~1.20,加医用乙醇至乙醇浓度为20%~85%,搅拌,静置或离心,取上清液脱色,回收乙醇后层析柱分离所需成分,获得有效部位A;
步骤2:将处方量的金银花和菊花用3~20倍量10%~95%乙醇有机溶剂回流提取3~5次,回收乙醇,低温减压浓缩,脱色,柱层析分离所需成分,获得有效部位B;或将处方量的金银花和菊花用3~20倍量水,煎煮提取3~5次,分离煎煮液,低温减压浓缩至比重1.05~1.20,加医用乙醇至乙醇浓度为20%~85%,脱色,回收乙醇后柱层析分离所需成分,获得有效部位B;
步骤3:合并有效部位A、B,得中药复方提取的有效部位。
10.一种权利要求1~8所述治疗激素依赖性皮炎的中药复方外用制剂在治疗激素依赖性皮炎的药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810511418.7A CN108403932B (zh) | 2018-05-24 | 2018-05-24 | 一种治疗激素依赖性皮炎的中药复方外用制剂及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810511418.7A CN108403932B (zh) | 2018-05-24 | 2018-05-24 | 一种治疗激素依赖性皮炎的中药复方外用制剂及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108403932A true CN108403932A (zh) | 2018-08-17 |
| CN108403932B CN108403932B (zh) | 2021-03-30 |
Family
ID=63140528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810511418.7A Active CN108403932B (zh) | 2018-05-24 | 2018-05-24 | 一种治疗激素依赖性皮炎的中药复方外用制剂及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108403932B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111903605A (zh) * | 2020-07-27 | 2020-11-10 | 广州市皮肤病防治所(广州市性病防治监测中心) | 一种诱导的sd大鼠激素依赖性皮炎模型及其测定方法 |
| CN115192589A (zh) * | 2022-07-13 | 2022-10-18 | 滴可安(杭州)生物技术有限公司 | 一种新异甘草苷在制备银屑病治疗药物中的应用 |
| CN118873636A (zh) * | 2024-07-10 | 2024-11-01 | 广州天韵实业有限公司 | 一种用于治疗激素性皮炎的中药组合物及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101209318A (zh) * | 2007-12-21 | 2008-07-02 | 尹凤媛 | 一种治疗激素依赖性皮炎及皮肤瘙痒的中药外用制剂 |
| CN103316251A (zh) * | 2013-06-24 | 2013-09-25 | 乔浩 | 治疗激素依赖性皮炎的中药外用制剂及其制备方法 |
| CN105055768A (zh) * | 2015-07-07 | 2015-11-18 | 中国人民解放军第四军医大学 | 一种治疗瘢痕的中药复方外用制剂及其制备方法和应用 |
| CN106074898A (zh) * | 2016-07-07 | 2016-11-09 | 曹蕊 | 一种激素依赖性皮炎的外用药物及制备方法 |
-
2018
- 2018-05-24 CN CN201810511418.7A patent/CN108403932B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101209318A (zh) * | 2007-12-21 | 2008-07-02 | 尹凤媛 | 一种治疗激素依赖性皮炎及皮肤瘙痒的中药外用制剂 |
| CN103316251A (zh) * | 2013-06-24 | 2013-09-25 | 乔浩 | 治疗激素依赖性皮炎的中药外用制剂及其制备方法 |
| CN105055768A (zh) * | 2015-07-07 | 2015-11-18 | 中国人民解放军第四军医大学 | 一种治疗瘢痕的中药复方外用制剂及其制备方法和应用 |
| CN106074898A (zh) * | 2016-07-07 | 2016-11-09 | 曹蕊 | 一种激素依赖性皮炎的外用药物及制备方法 |
Non-Patent Citations (5)
| Title |
|---|
| 周兰: "中药外洗治疗手足激素依赖性皮炎疗效观察", 《岭南皮肤性病科杂志》 * |
| 张丰川等: "《当代中医皮肤科临床家丛书 第3辑 李元文》", 31 January 2017, 中国医药科技出版社 * |
| 皮先明: "《皮肤病性病学中西医结合治疗》", 31 January 2013, 人民军医出版社 * |
| 范瑞强: "面部激素依赖性皮炎中医治疗思路与进展", 《中国医学文摘(皮肤科学)》 * |
| 韩冬雪: "中西医结合治疗面部激素依赖性皮炎临床观察", 《长春中医药大学学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111903605A (zh) * | 2020-07-27 | 2020-11-10 | 广州市皮肤病防治所(广州市性病防治监测中心) | 一种诱导的sd大鼠激素依赖性皮炎模型及其测定方法 |
| CN115192589A (zh) * | 2022-07-13 | 2022-10-18 | 滴可安(杭州)生物技术有限公司 | 一种新异甘草苷在制备银屑病治疗药物中的应用 |
| CN118873636A (zh) * | 2024-07-10 | 2024-11-01 | 广州天韵实业有限公司 | 一种用于治疗激素性皮炎的中药组合物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108403932B (zh) | 2021-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102091203B (zh) | 一种治疗难愈性创面的外用中药制剂及其制备方法 | |
| CN102049008B (zh) | 一种治疗黄褐斑的中药组合物及其制备方法 | |
| CN102988264B (zh) | 银杏叶祛斑美白霜及其制备方法 | |
| CN103041173B (zh) | 一种治疗皮炎、湿疹的中药外用制剂及其制备方法 | |
| CN103169928B (zh) | 治疗痛经的外用中药组合物及其制备方法和应用 | |
| CN102048894A (zh) | 一种治疗烧伤的中药组合物及其制备方法 | |
| CN103751663B (zh) | 一种治疗肛周湿疹的中药外用制剂及其制备方法 | |
| CN105055768A (zh) | 一种治疗瘢痕的中药复方外用制剂及其制备方法和应用 | |
| CN105496917A (zh) | 一种积雪草抗皱面霜及其制备方法 | |
| CN102000164B (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
| CN108403932A (zh) | 一种治疗激素依赖性皮炎的中药复方外用制剂及其制备方法和应用 | |
| CN104127813A (zh) | 一种治疗气血两虚型褥疮的中药组合物及其制备方法 | |
| CN105497261A (zh) | 一种外用贴剂基质及该基质制成的外用贴剂和助眠贴 | |
| CN102178781B (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法 | |
| CN106074959A (zh) | 一种缓解黑眼圈的中药组合物及其制备方法 | |
| CN105213584A (zh) | 一种治疗湿疹的中药组合物及其制备方法 | |
| CN1090932C (zh) | 一种面部外用软膏及其制备方法 | |
| CN105687432A (zh) | 一种中药组合物在制备治疗湿疹药物中的用途 | |
| CN101757104B (zh) | 一种治疗银屑病的药物 | |
| CN113244356A (zh) | 用于治疗银屑病的中药组合物 | |
| CN105616984A (zh) | 一种益母草去皱美容膏及其制备方法 | |
| CN106038802A (zh) | 治疗妇女卵巢早衰的中药组合物制备方法及其组合物 | |
| CN105233056A (zh) | 一种清热除湿、利胆排毒的大黄口服液及其制备方法 | |
| CN106692458A (zh) | 治疗痤疮的药物组合物及其制备方法与应用 | |
| CN102091254A (zh) | 一种用于面部整容后消肿的中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |